Abstract
Fibrous dysplasia is proliferation of fibrous tissue within the bone marrow causing osteolytic lesions and pathologic fractures. Recently, second generation bisphosphonates have shown promise in the treatment of patients with fibrous dysplasia. In the current study, six patients with fibrous dysplasia were treated with either oral alone or oral and intravenous bisphosphonates. The participants were observed for changes in N-telopeptide, pain score, and radiographic changes. In the current study, the combination bisphosphonate therapy diminished pain, prevented fractures, lowered N-telopeptide values, and led to partial resolution of fibrous dysplasia lesions.
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Alendronate / administration & dosage
-
Alendronate / therapeutic use*
-
Biomarkers / urine
-
Bone and Bones / drug effects
-
Collagen / urine
-
Collagen Type I
-
Diphosphonates / administration & dosage
-
Diphosphonates / therapeutic use*
-
Female
-
Fibrous Dysplasia of Bone / diagnostic imaging
-
Fibrous Dysplasia of Bone / drug therapy*
-
Follow-Up Studies
-
Fractures, Spontaneous / prevention & control
-
Humans
-
Injections, Intravenous
-
Male
-
Middle Aged
-
Osteogenesis / drug effects
-
Osteolysis / prevention & control
-
Pain Measurement
-
Pamidronate
-
Peptides / urine
-
Radiography
-
Statistics, Nonparametric
Substances
-
Biomarkers
-
Collagen Type I
-
Diphosphonates
-
Peptides
-
collagen type I trimeric cross-linked peptide
-
Collagen
-
Pamidronate
-
Alendronate